Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis

BMC Anesthesiology

Volumn 7, Issue , 2007, Pages

  Costa, Vania ^a   Brophy, James M ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PLACEBO;

APACHE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMBASE; HIGH RISK PATIENT; HUMAN; MEDLINE; MONTE CARLO METHOD; MORTALITY; PROBABILITY; REVIEW; RISK ASSESSMENT; SEPSIS; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 34547473024     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-7-5     Document Type: Review

References (59)

1. Lyseng-Williamson KA Perry CM Drotrecogin alfa (activated) Drugs 2002 62 617-30 discussion 631-2 10.2165/00003495-200262040-00006 11893230
2. Food and Drug Administration: FDA Clinical Review. Drotrecogin alfa (activated) [Recombinant human activated protein C (rhAPC)] XIGRIS (TM) 2001. Parts 1 and 2 http://www.fda.gov/cder/biologics/review/ droteli112101r1.pdf Last access: August 2006
3. United States Food and Drug Administration Drotrecogin alfa (activated) letter of approval http://www.fda.gov/cder/foi/appletter/2001/ droteli112101L.pdf November 21st 2001. Last access: July 2006
4. European Medicines Agency. Xigris product information http://www.emea.eu.int/humandocs/Humans/EPAR/xigris/Xigris.htm
5. Health Canada. Notice of Compliance - Xigris - 31-01-2003 http://www.nocdatabase.ca/ Last access: July 2006
6. Mackenzie AF Activated protein C: Do more survive? Intensive Care Med 2005 31 1624-6 10.1007/s00134-005-2829-4 16228174
7. Smith B Drotrecogin alfa: Too early to give it early Emerg Med Australas 2005 17 179-80 10.1111/j.1742-6723.2005.00713.x 15796737
8. Angus DC Laterre PF Helterbrand J Ely EW Ball DE Garg R Weissfeld LA Bernard GR The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis Crit Care Med 2004 32 2199-206 10.1097/ 01.CCM.0000114816.62331.08 15640631
9. Drabinski A Williams G Formica C Observational evaluation of health state utilities among a cohort of sepsis patients Value in Health 2001 4 128-9 10.1046/j.1524-4733.2001.40202-165.x
10. Baltussen RMPM Hutubessy RCW Evans DB Murray CJM Uncertainty in cost-effectiveness analysis International Journal of Technology Assessment in Health Care 2002 18 112-9 11987434
11. Glick HA Briggs AH Polsky D Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses Expert Rev. Pharmacoeconomics Outcome Res 2001 1 25-36 10.1586/14737167.1.1.25
12. Stinnett AA Mullahy J Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis Medical Decision Making 1998 18 S68-S80 10.1177/0272989X9801800209 9566468
13. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001 344 699-709 10.1056/NEJM200103083441001 11236773
14. Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL Francois B Guy JS Bruckmann M Rea-Neto A Rossaint R Perrotin D Sablotzki A Arkins N Utterback BG Macias WL Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005 353 1332-41 10.1056/NEJMoa050935 16192478
15. Johnston JA Determinants of mortality in patients with severe sepsis Med Decis Making 2005 25 374-86 10.1177/0272989X05278933 16061889
16. Bernard GR Macias WL Joyce DE Williams MD Bailey J Vincent JL Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis Crit Care 2003 7 155-63 270661 12720562 10.1186/cc2167
17. Laterre PF Garber G Levy H Wunderink R Kinasewitz GT Sollet JP Maki DG Bates B Yan SC Dhainaut JF Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study Crit Care Med 2005 33 952-61 10.1097/01.CCM.0000162381.24074.D7 15891319
18. Macias WL Vallet B Bernard GR Vincent JL Laterre PF Nelson DR Derchak PA Dhainaut JF Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis Crit Care Med 2004 32 2385-91 10.1097/ 01.CCM.0000147440.71142.AC 15599140
19. Barie PS Williams MD McCollam JS Bates BM Qualy RL Lowry SF Fry DE Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis Am J Surg 2004 188 212-20 10.1016/ j.amjsurg.2004.06.008 15450822
20. Ely EW Laterre PF Angus DC Helterbrand JD Levy H Dhainaut JF Vincent JL Macias WL Bernard GR Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 2003 31 12-9 10.1097/00003246-200301000-00002 12544987
21. Dhainaut JF Laterre PF LaRosa SP Levy H Garber GE Heiselman D Kinasewitz GT Light RB Morris P Schein R Sollet JP Bates BM Utterback BG Maki D The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results Crit Care Med 2003 31 2291-301 10.1097/ 01.CCM.0000085089.88077.AF 14501959
22. Dhainaut JF Laterre PF Janes JM Bernard GR Artigas A Bakker J Riess H Basson BR Charpentier J Utterback BG Vincent JL Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial Intensive Care Med 2003 29 894-903 12712239
23. Ely EW Angus DC Williams MD Bates B Qualy R Bernard GR Drotrecogin alfa (activated) treatment of older patients with severe sepsis Clin Infect Dis 2003 37 187-95 10.1086/375775 12856210
24. Dhainaut JF Yan SB Joyce DE Pettila V Basson B Brandt JT Sundin DP Levi M Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation J Thromb Haemost 2004 2 1924-33 10.1111/ j.1538-7836.2004.00955.x 15550023
25. Shorr AF Bernard GR Dhainaut JF Russell JR Macias WL Nelson DR Sundin DP Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome Crit Care 2006 10 R92 1550956 16780598 10.1186/cc4946
26. Levy H Laterre PF Bates B Qualy RL Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated) Crit Care 2005 9 R502-7 1297614 16277711 10.1186/cc3778
27. Cone LA Stone RA Jesser K Nelson R Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis J Investig Med 2004 52 470-4 15651264
28. Laterre PF Levy H Clermont G Ball DE Garg R Nelson DR Dhainaut JF Angus DC Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial Crit Care Med 2004 32 2207-18 15640632
29. Opal SM Garber GE LaRosa SP Maki DG Freebairn RC Kinasewitz GT Dhainaut JF Yan SB Williams MD Graham DE Nelson DR Levy H Bernard GR Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin Infect Dis 2003 37 50-8 10.1086/375593 12830408
30. Vincent JL Angus DC Artigas A Kalil A Basson BR Jamal HH Johnson G 3rd Bernard GR Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial Crit Care Med 2003 31 834-40 10.1097/ 01.CCM.0000051515.56179.E1 12626993
31. Wiedermann CJ Kaneider NC A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients withsepsis BMC Emerg Med 2005 5 7 1266358 16225672 10.1186/1471-227X-5-7
32. Friedrich JO Drotrecogin alfa (activated) in severesepsis N Engl J Med 2006 354 94 6 author reply 94-6 10.1056/NEJMc052759 16394311
33. Sashegyi A Trzaskoma BL Nelson DR Williams MD Macias W International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: Component trials and statistical methods for INDEPTH Curr Med Res Opin 2006 22 1001-12 10.1185/030079906X104713 16709322
34. Fowler RA Hill-Popper M Stasinos J Petrou C Sanders GD Garber AM Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis J Crit Care 2003 18 181-91 discussion 191-4 10.1016/ j.jcrc.2003.08.009 14595571
35. Riou Franca L Launois R Le Lay K Aegerter P Bouhassira M Meshaka P Guidet B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Int J Technol Assess Health Care 2006 22 101-8 16673686
36. Hjelmgren J Persson U Tennvall GR Local treatment pattern versus trial-based data: A cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Am J Ther 2005 12 425-30 10.1097/01.mjt.0000141605.27943.8d 16148428
37. Davies A Ridley S Hutton J Chinn C Barber B Angus DC Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Anaesthesia 2005 60 155-62 10.1111/ j.1365-2044.2004.04068.x 15644013
38. Betancourt M McKinnon PS Massanari RM Kanji S Bach D Devlin JW An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures Pharmacoeconomics 2003 21 1331-40 10.2165/00019053-200321180-00004 14750900
39. Neilson AR Burchardi H Chinn C Clouth J Schneider H Angus D Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany J Crit Care 2003 18 217-27 10.1016/ j.jcrc.2003.10.005 14691895
40. Manns BJ Lee H Doig CJ Johnson D Donaldson C An economic evaluation of activated protein C treatment for severe sepsis N Engl J Med 2002 347 993-1000 10.1056/NEJMsa020969 12324556
41. Angus DC Linde-Zwirble WT Clermont G Ball DE Basson BR Ely EW Laterre PF Vincent JL Bernard G van Hout B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Crit Care Med 2003 31 1-11 10.1097/00003246-200301000-00001 12544986
42. Green C Dinnes J Takeda AL Cuthbertson BH Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Int J Technol Assess Health Care 2006 22 90-100 16673685
43. Carlet J Prescribing indications based on successful clinical trials in sepsis: A difficult exercise Crit Care Med 2006 34 525-9 10.1097/ 01.CCM.0000198329.85851.8E 16424736
44. Green C Dinnes J Takeda A Shepherd J Hartwell D Cave C Payne E Cuthbertson BH Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: A systematic review and economic evaluation Health Technol Assess 2005 1-126 15774234
45. Mackenzie AF Conflict of opinion - is PROWESS real progress? Intensive Care Med 2006 32 610-2 10.1007/s00134-006-0090-0 16508753
46. Wiedermann CJ When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated) Intensive Care Med 2006 32 604 10.1007/ s00134-006-0086-9 16508757
47. Taylor B Burns D van de Wal BW MBewu T Keeton GR Should health care money in South Africa be spent on drotrecogin alfa? S Afr Med J 2003 93 500-1 12939917
48. Carlet J A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker Intensive Care Med 2004 30 994 author reply 995 10.1007/s00134-004-2245-1 15083270
49. Manocha S Walley KR Activated protein C: Beyond 28 days Crit Care Med 2004 32 2348-9 15640656
50. Vincent JL Sepsis in the ICU: Who needs progress? Intensive Care Med 2006 32 609 10.1007/s00134-006-0089-6 16508754
51. Hodgson RE Williams PG Foden AP Grolman D Drotrecogin alfa (activated) in South African private hospital ICUs S Afr Med J 2003 93 474-5 12939910
52. Levi M Benefit of recombinant human activated protein C beyond 28-day mortality: There is more to life than death Crit Care Med 2003 31 984-5 10.1097/01.CCM.0000055386.01914.0C 12627023
53. Dellinger RP Recombinant activated protein C: Decisions for administration Crit Care Med 2006 34 530-1 10.1097/ 01.CCM.0000199068.67569.B3 16424737
54. Dellinger RP Recombinant activated protein C: The key is clinical assessment of risk of death, not subset analysis Crit Care Med 2006 10
55. Morris PE Meeting unmet needs in patients with sepsis: The role of drotrecogin alfa (activated) Am J Crit Care 2003 12 94-7 12625165
56. Eichacker PQ Natanson C Danner RL Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly N Engl J Med 2006 355 1640-2 10.1056/NEJMp068197 17050887
57. Friedrich JO Adhikari NK Meade MO Drotrecogin alfa (activated): Does current evidence support treatment for any patients with severe sepsis? Crit Care 2006 10 145 1550958 16762040 10.1186/cc4947
58. Eichacker PQ Natanson C Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials Crit Care Med 2003 31 S94-6 10.1097/00003246-200301001-00013 12544982
59. Statistics Canada. Life tables, Canada andprovinces and territories 2000-2002 http://www.statcan.ca/english/freepub/84-537-XIE/tables.htm Last access: August 2006